Homologous Recombination Deficiency (HRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Homologous Recombination Deficiency (HRD) Market Outlook

Thelansis’s “Homologous Recombination Deficiency (HRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homologous Recombination Deficiency (HRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Homologous Recombination Deficiency (HRD) Overview

Homologous recombination deficiency (HRD) is a cellular phenotype characterized by the inability to repair double-strand DNA effectively breaks through the homologous recombination repair (HRR) pathway. This condition can arise from mutations in BRCA1, BRCA2, and other HRR pathway genes. Various tumor types, including breast, ovarian, prostate, and pancreatic cancers, have been linked to deficiencies in the HRR pathway. Cells lacking functional HRR must rely on alternative, less precise DNA repair pathways. These pathways can lead to widespread genomic alterations, including insertions, deletions, copy number changes, and structural rearrangements. Molecular techniques can detect these genomic scars, which are indicative of HRD. Alterations in these genes have been identified as potential “causes” of HRD, encompassing genetic and epigenetic events. HRR is a vital DNA repair mechanism that corrects various types of DNA damage, particularly double-strand breaks and interstrand cross-links, using the sister chromatid as a repair template. While other genes in the HRR pathway, such as ATM, PALB2, and RAD51, have also been linked to HRD, their associations with different cancers are less consistent than BRCA1/2. The FDA has approved multiple companion or complementary diagnostics. These diagnostics aim to aid in selecting appropriate PARP inhibitor (PARPi) treatments based on the HR status of patients. Among these diagnostics are FoundationOne CDx and the Myriad myChoice CDx test, which evaluate chromosomal instability. They help identify ovarian cancer patients who could benefit from an FDA-approved therapy. These assays take into account both the causes and consequences of HRR impairment, setting them apart from other FDA-approved tests like BRACAnalysis CDx, FoundationOne Liquid CDx, and FoundationOne CDx, which primarily focus on detecting potential causes of HRR impairment. Lynparza (olaparib), Zejula (niraparib), and Rubraca (rucaparib), these PARPi drugs utilize HRD as biomarkers for patient selection in both initial and recurrent cases of epithelial ovarian, fallopian tube, or primary peritoneal cancers.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Homologous Recombination Deficiency (HRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034